Clinical Trial Search

Primary: Change From Baseline in ZANarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Total Score at Week 10 — -8.7; -8.0; -9.2; -8.9 units on a scale — p=0.4994

Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Change in Revised Fibromyalgia Impact Questionnaire (FIQR) Score From Baseline to After Treatment Occurring at Weeks 8 and 18 — 4.37; 12.1 Score

Primary: Change From Baseline to Week 16 in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in the First Second (FEV1) as Measured in the Study Clinic — 0.148; 0.116; 0.112…

Primary: Post-biopsy Pain (VAS-P) — 1; 1 score on a scale

Primary: Event-free Survival (EFS)- Number of Participants With an Event — 31; 15 Participants

Primary: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months — 10 Participants

Primary: Number of Participants for Which an Assessment of PET Based Therapeutic Response to HIFU is Successfully Obtained — 14; 14 Participants

Primary: Change in Suicidal Ideation — 8.90; 8.97; 12.27; 7.36 score on a scale — p=.30

Primary: Distribution of the Last Interval With no Disease Activity up to Week 32 - Study Eye — 141; 73; 131; 147 Participants — p=<0.0001

Primary: Five Factor Mindfulness Questionnaire (FFMQ) — 111.6 score on a scale

Primary: Change in Severity Score of Protective Qi Deficiency — 2.66; 2.58; 2.50; 2.57 units on a scale — p=<0.0001

Primary: Safety at 30 Days — 1 Participants

Primary: Number of Adverse Events — 1 Participants